Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

UK statisticians and trialists reach out to the clinical trial community in an awareness-raising paper published this week as a first step in changing practice. They promote the use of adaptive designs in early-phase clinical trials to improve trial efficiency, which will benefit patients.

Human clinical trials should be based on the best possible evidence. However, changing the design used in early-phase trials has proved challenging, even when newer methods increase the chance that the trial will get the correct answer. The NIHR Statisticians Research Group on Early Phase Clinical Trials, which includes CSM statisticians, is on a mission to help clinical trialists to underpin their phase I trials with best-practice designs. They target clinicians, nurses and statisticians in an open-access motivational awareness-raising paper published in the British Journal of Cancer this week.    

The first time a promising new medical treatment leaves the laboratory and is tested in a person is in a phase I dose-finding trial. These trials give a series of human participants different doses of the drug to find out which doses are not too toxic for humans. 

Phase I trials typically use rules set before the trial starts to decide what dose each participant gets. However, 20 years of statistics research has overwhelmingly shown that it is better to use mathematical models that decide each participant’s dose using the information gathered in the trial up until that participant. Although pharmaceutical companies have switched to using these models, academic trials still tend to use rules. Only 6.7% of all dose-finding trials use best-practice model-based designs!

CSM’s Sharon Love is a member of the NIHR Statisticians Research Group and a co-author on the motivational paper. She says, “This is the start of a concerted effort by UK statisticians and trialists using these designs to make them accessible to all. This first paper explains the benefits of using model-based designs and how to overcome barriers to using them. In collaboration with the MRC Network of Hubs for Trials Methodology Research's Adaptive Designs Working Group, we have submitted a second paper that will take readers through each step of the design of model-based design using non-statistical language.”     

The NIHR Statisticians Research Group plans to offer courses in 2018 to train trialists in using model-based designs for phase I trials. As these best-practice methods are used by the trials research community, the Group plans to conduct methodology research on the challenges that trialists discover when using these methods.

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.